Why Is ADC Therapeutics Plunging Today

Benzinga_recent_news12-04

ADC Therapeutics SA (NYSE:ADCT) is facing a sharp market reaction as investors digest the latest trial results for its cancer drug, Zynlonta. Despite promising efficacy data from the ongoing LOTIS-7 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588029698?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/03/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-04 03:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588029698","market":"sh","top_or_hot":-1,"title":"Why Is ADC Therapeutics Plunging Today","media":"Benzinga_recent_news","content":"<div>\n<p>ADC Therapeutics SA (NYSE:ADCT) is facing a sharp market reaction as investors digest the latest trial results for its cancer drug, Zynlonta.\nDespite promising efficacy data from the ongoing LOTIS-7 ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is ADC Therapeutics Plunging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is ADC Therapeutics Plunging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-04 03:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ADC Therapeutics SA (NYSE:ADCT) is facing a sharp market reaction as investors digest the latest trial results for its cancer drug, Zynlonta.\nDespite promising efficacy data from the ongoing LOTIS-7 ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CR","symbol_name":"crane","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today","article_id":"2588029698","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/03/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49193928/why-is-adc-therapeutics-plunging-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2588029698","pubTimestamp":1764790800,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, with enrollment ongoing into 2026.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CR":"crane","BK4161":"工业机械","LENZ":"Therapeutics","ORR":"Militia Long/Short Equity ETF","BK4139":"生物科技","BK4007":"制药","BK4231":"零售房地产信托","BK4505":"高瓴资本持仓","BK4080":"零售业房地产投资信托","BK4213":"石油与天然气的勘探与生产","ADC":"艾格里房产","BK4539":"次新股","SD":"SandRidge Energy","ADCT":"ADC Therapeutics SA","PR":"Permian Resources Corp"},"translate_title":"为什么ADC疗法今天暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CR":1,"ORR":1,"PR":1,"ADCT":1,"LENZ":1.5,"SD":1,"ADC":1.5},"content_text":"ADC Therapeutics SA (NYSE:ADCT) is facing a sharp market reaction as investors digest the latest trial results for its cancer drug, Zynlonta.\nDespite promising efficacy data from the ongoing LOTIS-7 trial, including high response rates among patients, the stock plunged as concerns about the safety profile and trial progress overshadowed the positive findings.\nOn Wednesday, the comany shared updated data from the LOTIS-7 Phase 1b open-label trial of Zynlonta in combination with glofitamab (Columvi) for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).\nAs of the November 17, 2025, cutoff date, a total of 49 patients were efficacy evaluable with a minimum of 6 months of follow-up from treatment initiation.\nBest overall response rate (ORR) was 89.8% (44/49 patients).\nComplete response (CR) rate was 77.6% (38/49 patients) \nStrong efficacy in both the relapsed and primary refractory populations across both dose levels\nFourteen patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 13 patients, respectively). Of the eight patients previously treated with CAR-T, 6 achieved a CR.\nThe combination was generally well tolerated with a manageable safety profile.\nEnrollment in the LOTIS-7 clinical trial is ongoing, with complete enrollment of approximately 100 patients at the selected 150 µg/kg dose expected during the first half of 2026.\nThe Company plans to share full data at a medical meeting and submit for publication by the end of 2026.\nADCT Price Action: ADC Therapeutics shares were down 23.15% at $3.53 at the time of publication on Wednesday, according to Benzinga Pro data.\nRead Next:\nPhoto by Aunt Spray via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588029698","isCrawlerRequest":true}